Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Faller
Bernard Faller, Obermorschwiller FR
| Patent application number | Description | Published |
|---|---|---|
| 20090305995 | AGONISTS AND ANTAGONISTS OF THE SOMATOSTATIN RECEPTOR - The invention relates to substituted F3-Phe-trp-F 3-Lys-beta-tri-peptides and derivatives thereof, a process for their preparation, pharmaceutical preparations which contain these compounds which are agonists/antagonists of somatostatin receptors, as active agents for the treatment of disorders which can be influenced by a modulation of somatostatin receptor activity, in particular somatostatin receptor sst4 activity, by the compounds of the invention. | 12-10-2009 |
Marc Faller, Hegenheim FR
| Patent application number | Description | Published |
|---|---|---|
| 20110288251 | POLYMERISATION INITIATOR - The invention relates to novel O-dialkylamino-isoureas and polymerizable compositions comprising these O-dialkylamino-isoureas of compounds of the general formula (I). The invention further relates to the use of O-dialkylamino-isoureas as polymerization initiators, especially to prepare coatings or for controlled degradation of polyolefins. | 11-24-2011 |
Thomas Faller, Reinach CH
| Patent application number | Description | Published |
|---|---|---|
| 20100234467 | METHODS FOR IMPROVING BIOAVAILABILITY OF A RENIN INHIBITOR - The present invention provides a method for improving the bioavailability of a renin inhibitor, preferably, of a ε-amino-γ-hydroxy-ω-aryl-alkanoic acid derivative, which method comprises co-administering to a mammal, especially a human, in need of such treatment, a combination of a renin inhibitor, or a pharmaceutically acceptable salt thereof, and an MDR | 09-16-2010 |
William Faller, Dublin IE
| Patent application number | Description | Published |
|---|---|---|
| 20090093424 | Markers for melanoma - A method of diagnosing melanoma and/or monitoring melanoma progression, in particular for determining whether the melanoma is likely to have metastatic capabilities, in a subject includes the steps of in a test sample determining the methylation status of FABP5 wherein methylation of the gene indicates a positive diagnosis of melanoma and/or increased methylation of the gene indicates the progression of melanoma. Methods of monitoring melanoma progression may also incorporate measuring the expression levels of FABP5, with low levels of expression indicating a positive diagnosis of melanoma and/or lower levels of expression being indicative of progression of melanoma. Methods of treating melanoma in a subject comprise administering a therapeutically effective amount of a DNA methyltransferase inhibitor or a histone deacetylase inhibitor to the subject such that expression of FABP5 is increased. Microarrays for use in these diagnostic methods and compound screening methods based around monitoring methylation and/or expression of FABP5 are also envisaged. | 04-09-2009 |